News & Updates

Show Multimedia Only
Dolutegravir knocks down HIV faster than bictegravir in French study

Dolutegravir knocks down HIV faster than bictegravir in French study

06 Oct 2026 byElvira Manzano

Final analysis of the BicDol study, presented at AIDS 2026, suggests that a first-line triple antiretroviral regimen containing dolutegravir suppresses HIV more rapidly than one containing bictegravir, particularly among patients with the highest viral loads.

06 Oct 2026
Delayed ART initiation, socioeconomic factors predict HIV care disengagement

Delayed ART initiation, socioeconomic factors predict HIV care disengagement

01 Oct 2026 byStephen Padilla

Delayed initiation of antiretroviral therapy (ART) and some socioeconomic factors contribute to disengagement from HIV care, suggests a study in the Philippines.

01 Oct 2026